

IDS of 7/2/07

PTO/SB/08A/B (09-06)  
Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/801,648-Conf. #2232
				Filing Date	March 17, 2004
				First Named Inventor	Hsiang-Fu Kung
				Art Unit	1633
				Examiner Name	R. M. Kelly
Sheet	1	of	1	Attorney Docket Number	V9661.0074

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country, Code <sup>3</sup> -Number-Kind Code <sup>2</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
RMK	CI2	Chen et al., 2003, "Gene therapy for new bone formation using adeno-associated viral bone morphogenetic protein-2 vectors", <i>Gene Ther</i> 10:1345-1353.			
	CJ2	Gafni et al., 2004, "Gene therapy platform for bone regeneration using an exogenously regulated, AAV-2-based gene expression system", <i>Mol Ther</i> 9(4):587-595.			
	CK2	Moutsatsos et al., 2001, "Exogenously regulated stem cell-mediated gene therapy for bone regeneration", <i>Mol Ther</i> 3(4):449-461.			
	CL2	Turgeiman et al., 2001, "Engineered human mesenchymal stem cells: a novel platform for skeletal cell mediated gene therapy", <i>J Gene Med</i> 3:240-251.			
	CM2	Yasko et al., 1992, "The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP-2)", <i>J Bone Joint Surg Am</i> 74.A(5):659-670.			
RMK	CN2	Yue et al., 2005, "BMP2 gene therapy on the repair of bone defects of aged rats", <i>Calcif Tissue Int</i> 77:395-403.			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Robert M. Kelly</i>	Date Considered	9/7/07
-----------------------	------------------------	--------------------	--------